Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02523196
Other study ID # 15-0520
Secondary ID UL1TR001082
Status Completed
Phase Phase 3
First received
Last updated
Start date March 2016
Est. completion date February 23, 2017

Study information

Verified date August 2021
Source University of Colorado, Denver
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study plans to learn more about a new test to look at liver function, the HepQuant-Shunt (HQ-Shunt). The HQ-Shunt is being evaluated for safety and effectiveness as an alternative to Hepatic Venous Pressure Gradient testing in patients with liver disease.


Description:

The goal of this study is to demonstrate the HQ-SHUNT is safe, simple to administer, noninvasive, cost-effective, and well tolerated by patients. This study will compare the HQ-SHUNT to Hepatic Venous Pressure Gradient (HVPG) testing. In this study, 100 consecutive patients with various etiologies of liver disease who have undergone technically successful HVPG testing as standard of care will also undergo HQ-SHUNT testing.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date February 23, 2017
Est. primary completion date February 23, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Liver disease patient scheduled to have an Hepatic Venous Pressure Gradient (HVPG) procedure - At time of enrollment, being between the ages of 18 and 75 Exclusion Criteria: - Concomitant treatment with both a beta blocker and an ACE inhibitor - Concurrent hepatic malignancy. Patients with a history of treated HCC can be included if there is no evidence of recurrent disease at the time of this study. - Unstable angina or history of myocardial infarction or congestive heart failure within 6 months prior to enrollment into this study - Renal insufficiency with chronic kidney disease stage 4 or 5 (GFR < 30 mL/min/1.73m2) - Crohn's disease or any active intestinal inflammatory condition - Having had an ileal resection - Diabetic Gastroparesis - Pregnancy or intent to become pregnant. Urine pregnancy tests will be performed prior to HQ SHUNT testing. - Inability to consent for one's self

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
HepQuant-SHUNT (Drug and Device) #65,123 (4D-cholate) and IND #65,121 (13C-cholate)
The HQ-SHUNT test is being evaluated for safety and effectiveness as an alternative to Hepatic Venous Pressure Gradient (HVPG) testing in patients with liver disease
Device:
Hepatic Venous Pressure Gradient (HVPG)
Hepatic Venous Pressure Gradient (HVPG) is a test for patients with liver disease

Locations

Country Name City State
United States University of Colorado Denver (Leprino Building) Aurora Colorado

Sponsors (1)

Lead Sponsor Collaborator
University of Colorado, Denver

Country where clinical trial is conducted

United States, 

References & Publications (1)

Everson GT, Shiffman ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA, Lauriski S, Curto TM, Stoddard A, Wright EC; HALT-C Trial Group. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the H — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Results of HepQuant SHUNT Test: Elimination Rate (IV Phase 1 Only; Min-1) Compare Disease Severity Index (DSI) from HQ-SHUNT for defining patients with (HVPG =6 mmHg) and without (HVPG <6 mmHg) portal hypertension. Up to 90 minutes
Primary Results of HepQuant SHUNT Test: Systemic Clearance Compare Disease Severity Index (DSI) from HQ-SHUNT for defining patients with (HVPG =6 mmHg) and without (HVPG <6 mmHg) portal hypertension. Systemic Clearance (13C-CA; ml min-1) Up to 90 minutes
Primary Results of HepQuant SHUNT Test: Apparent Portal Clearance Compare Disease Severity Index (DSI) from HQ-SHUNT for defining patients with (HVPG =6 mmHg) and without (HVPG <6 mmHg) portal hypertension. Up to 90 minutes
Primary Results of HepQuant SHUNT Test: Systemic Hepatic Filtration Rate Compare Disease Severity Index (DSI) from HQ-SHUNT for defining patients with (HVPG =6 mmHg) and without (HVPG <6 mmHg) portal hypertension. Up to 90 minutes
Primary Results of HepQuant SHUNT Test: Portal Hepatic Filtration Rate Compare Disease Severity Index (DSI) from HQ-SHUNT for defining patients with (HVPG =6 mmHg) and without (HVPG <6 mmHg) portal hypertension. Up to 90 minutes
Primary Results of HepQuant SHUNT Test: SHUNT Compare Disease Severity Index (DSI) from HQ-SHUNT for defining patients with (HVPG =6 mmHg) and without (HVPG <6 mmHg) portal hypertension.
SHUNT% is The percent of the oral dose of cholate that escapes hepatic extraction
Up to 90 minutes
Primary Results of HepQuant SHUNT Test: DSI Score Compare Disease Severity Index (DSI) from HQ-SHUNT for defining patients with (HVPG =6 mmHg) and without (HVPG <6 mmHg) portal hypertension.
DSI range is from 0 to 50. 0 implies no disease; 50 implies severe end-stage disease.
Up to 90 minutes
Primary Results of HepQuant SHUNT Test: STAT Compare HepQuant STAT test from HQ-SHUNT for defining patients with (HVPG =6 mmHg) and without (HVPG <6 mmHg) portal hypertension. HepQuant STAT is a simple "drink and draw" blood-based clearance test that quantifies hepatic impairment from early through late stages of disease. 60 minutes
Secondary Survey Patients on Their Experience of Having Both HQ-SHUNT and HVPG Procedures. Overall experience and willingness to repeat 0-10 Scale 0 being no pain, 10 being severe pain 0 being no discomfort, 10 being severe discomfort 0 being no interference with daily life, 10 being unable to carry on activities 0 being very negative experience, 10 being very positive experience 0 being definitely not wanting to have the test again, 10 being very willing to have the test again Immediately post HepQuant SHUNT test (Baseline up to Day 60)
Secondary Hours for Test Number of hours it took for subjects to complete each test Baseline, up to Day 60
See also
  Status Clinical Trial Phase
Completed NCT02798861 - Controlled Attenuation Parameter (CAP) in Liver Allografts
Completed NCT01968395 - Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Phase 4
Completed NCT01437969 - Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Infection naïve to Treatment.
Recruiting NCT00155376 - Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography Phase 4
Recruiting NCT00172705 - Quantitative Diagnosis of Fatty Liver by Dual Energy CT Technique N/A
Completed NCT04185454 - Estimation of Minimum Efficacy Daily Dose of Jarlsberg Cheese N/A
Completed NCT02506335 - Liver Function Measured by HepQuant-SHUNT in the Prediction of Outcomes in Patients With Heart Disease Early Phase 1
Completed NCT02520609 - Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Completed NCT02306018 - Evaluation of a New Calibrated Pulse Wave Analysis Method(EV1000™/volumeView™) for Cardiac Output Monitoring in Adult Liver Transplantation N/A
Completed NCT01970904 - Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients N/A
Completed NCT01988753 - Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
Terminated NCT00741117 - Conjugated Hyperbilirubinemia and Pulse Oximetry N/A
Enrolling by invitation NCT01483248 - Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis Phase 1/Phase 2
Completed NCT00074386 - Kidney and Liver Transplantation in People With HIV N/A
Completed NCT00245830 - Ischemic Preconditioning of Liver in Cadaver Donors N/A
Completed NCT02329821 - Change of Lactate Concentration During Hartmann Solution Infusion for Hepatic Resection N/A
Completed NCT01303549 - Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients Phase 4
Completed NCT01650181 - Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Phase 4
Completed NCT00799851 - A Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection for Esophageal Varices Phase 4
Completed NCT00058890 - Gabapentin to Treat Itch in Patients With Liver Disease Phase 3